-
公开(公告)号:EP4452220A1
公开(公告)日:2024-10-30
申请号:EP22839442.5
申请日:2022-12-23
申请人: Subintro Limited
IPC分类号: A61K9/00 , A61K9/12 , A61K9/10 , A61K47/12 , A61K47/26 , A61K47/38 , A61K47/36 , A61K47/10 , A61P31/16 , A61K31/5377 , A61K31/245 , A61K31/4045 , A61K31/706 , A61K31/7068 , A61K31/513
-
公开(公告)号:EP3668522B1
公开(公告)日:2024-09-11
申请号:EP18846700.5
申请日:2018-08-17
IPC分类号: A61K31/7088 , A61K39/145 , A61K9/51 , G01N33/50 , A61P31/16 , A61K47/69
CPC分类号: A61K31/713 , A61K2039/5320130101 , A61K39/12 , A61K2039/5555520130101 , C12N2770/2413420130101 , Y02A50/30
-
3.
公开(公告)号:EP3498281B1
公开(公告)日:2024-08-28
申请号:EP17839530.7
申请日:2017-08-09
IPC分类号: A61K31/5383 , A61P43/00 , A61P31/16 , A61P31/12 , C07D498/14 , A61K9/00 , A61K9/70 , A61K9/20 , A61K9/48 , A61K9/16 , A61K9/06
CPC分类号: A61K31/5383 , A61P31/16 , A61P31/12 , A61P43/00 , C07D498/14 , A61K9/2018 , A61K9/4858 , A61K9/1623 , A61K9/0056 , A61K9/0095 , A61K9/0019 , A61K9/06 , A61K9/0014 , A61K9/0075 , A61K9/7038
-
公开(公告)号:EP4410788A1
公开(公告)日:2024-08-07
申请号:EP22875040.2
申请日:2022-09-29
申请人: Shanghai Institute of Materia Medica, Chinese Academy of Sciences , Wuhan Institute Of Virology, Chinese Academy of Sciences , Hainan Simcere Pharmaceutical Co., Ltd.
发明人: JIANG, Xiangrui , XU, Yechun , ZHANG, Leike , SU, Haixia , ZHANG, Qiumeng , ZHAO, Wenfeng , SHANG, Weijuan , SHEN, Jingshan , XIAO, Gengfu , JIANG, Hualiang
IPC分类号: C07D403/12 , C07D403/14 , C07D207/26 , C07D307/02 , C07D309/02 , C07D335/02 , A61K31/38 , A61P31/14 , A61P31/16 , A61P31/18
CPC分类号: A61K31/38 , A61P31/14 , A61P31/16 , A61P31/18 , C07D207/26 , C07D307/02 , C07D309/02 , C07D335/02 , C07D403/12 , C07D403/14
摘要: The present invention provides a compound represented by formula I, a racemate, an enantiomer, a diastereoisomer and a pharmaceutically acceptable salt thereof, and their use in preventing or treating a related disease caused by coronavirus and/or picornavirus infection.
-
5.
公开(公告)号:EP4408448A1
公开(公告)日:2024-08-07
申请号:EP22785734.9
申请日:2022-09-22
申请人: Biocodex
CPC分类号: A61K36/064 , A61P31/16 , A61P31/12 , A61P31/10 , A61P11/00 , A61K9/0053 , A61K9/0014 , A61K9/0043 , A61K9/0031 , A61K9/0019
-
-
7.
公开(公告)号:EP4408435A1
公开(公告)日:2024-08-07
申请号:EP22799860.6
申请日:2022-09-26
申请人: MVS Pharma GmbH
IPC分类号: A61K31/7048 , A61K31/11 , A61K31/732 , A61K31/734 , A61K31/015 , A61K31/05 , A61K31/35 , A61L9/00 , A61M15/00 , A61P31/00 , A61P31/04 , A61P31/12 , A61P31/14 , A61P31/16 , A61P31/20 , F24F8/15 , A61M15/02 , A61M15/08 , A61M11/00
CPC分类号: A61K31/35 , A61K31/015 , A61K31/05 , A61K31/11 , A61K31/7048 , A61P31/00 , A61P31/04 , A61P31/12 , A61P31/14 , A61P31/16 , A61P31/20 , F24F8/15 , A61M11/042 , A61M15/08 , A61M2205/8420130101 , A61M2250/0020130101 , A61M2205/58820130101 , A61M2205/020520130101 , A61M2205/5020130101 , A61M11/005 , A61M15/02 , A61M2209/1020130101 , A61K31/732 , A61K31/734 , A61L9/01 , A61L9/044 , A61L2209/1620130101
-
公开(公告)号:EP4401789A1
公开(公告)日:2024-07-24
申请号:EP22809653.3
申请日:2022-10-21
-
公开(公告)号:EP3810115B1
公开(公告)日:2024-07-17
申请号:EP19826531.6
申请日:2019-06-24
IPC分类号: C07D413/04 , C07D413/14 , A61K31/4025 , A61K31/4174 , A61K31/4196 , A61K31/444 , A61K31/496 , A61P31/10 , A61P31/16
CPC分类号: A61K31/444 , A61K31/496 , A61K31/4196 , A61K31/4174 , A61K31/4025 , A61K38/12 , A61P31/10 , C07D413/14 , C07D413/04
-
公开(公告)号:EP4389221A2
公开(公告)日:2024-06-26
申请号:EP24159464.7
申请日:2017-03-01
发明人: GLENN, Jeffrey S. , HAGEY, Rachel , PHAM, Edward
IPC分类号: A61P31/16
CPC分类号: A61K45/06 , A61K31/7084 , A61K31/7088 , C12N2310/1120130101 , C12N2310/31520130101 , C12N2310/323120130101 , A61P31/16 , C12N15/1131 , A61K31/7125
摘要: Methods of inhibiting influenza A virus in a sample are provided. Aspects of the methods include contacting a sample comprising viral RNA (vRNA) having a PSL2 motif with an effective amount of an agent that specifically binds the PSL2 motif to inhibit the influenza A virus. Also provided are methods of treating or preventing influenza A virus infection in a subject. Also provided are methods for screening a candidate agent for the ability to inhibit influenza A virus in a cell, the method comprising: contacting a sample with a candidate agent; and determining whether the candidate agent specifically binds to the PSL2 motif of vRNA. Also provided are compounds and pharmaceutical compositions comprising an oligonucleotide sequence complementary to a PB2 vRNA region that find use in the subject methods.
-
-
-
-
-
-
-
-
-